CTSK and pemphigus foliaceus: Except the well‐established supportive clinical strategies for treating ALI and PF progression, recombinant CTSK peptides would be a valuable potency to directly target PF progression, however, should be precisely administrated determined by the serum concentration of CTSK abundance, which could be further evaluated in the future study.